MindMed Rebrands as Definium Therapeutics, Prepares for Three Phase 3 Psychedelic Therapy Readouts in 2026
Key Insights
MindMed (search) has rebranded to Definium Therapeutics (search), reflecting its evolution as a leader in psychiatric drug development with a focus on psychedelic-based treatments.
The company expects topline data from three Phase 3 studies of DT120 (search) ODT for generalized anxiety disorder (search) and major depressive disorder (search) in 2026, targeting over 50 million affected Americans.
DT120 (search) ODT has received FDA Breakthrough Therapy Designation for GAD, positioning Definium to potentially enter the two largest psychiatric markets.
Mind Medicine (MindMed (search)) Inc. has rebranded as Definium Therapeutics (search), marking a strategic transformation as the company prepares for three pivotal Phase 3 data readouts in 2026 that could reshape psychiatric treatment. The rebrand reflects the company's evolution from an early-stage psychedelic research firm to a late-stage clinical leader positioned to bring novel therapies to market.
"Definium Therapeutics (search) reflects the core of who we've always been and where we're headed - disciplined execution, scientific leadership, and a vision to develop accessible treatments that can unlock healing at scale," said Rob Barrow, Chief Executive Officer of Definium Therapeutics. The company's shares now trade under the Nasdaq ticker symbol "DFTX."
Three Phase 3 Studies Target Major Psychiatric Markets
Definium is advancing DT120 (search) Orally Disintegrating Tablet (ODT) toward FDA submissions in generalized anxiety disorder (search) (GAD) and major depressive disorder (search) (MDD), which together affect over 50 million people in the U.S. The company's lead candidate has received FDA Breakthrough Therapy Designation for GAD, highlighting its potential clinical significance.
The anticipated 2026 milestones include:
- Second quarter 2026: Topline data from Voyage, the first Phase 3 study of DT120 ODT in GAD
- Second half 2026: Topline data from Panorama, the second Phase 3 study of DT120 ODT in GAD
- Mid-year 2026: Topline data from Emerge, the first Phase 3 study of DT120 ODT in MDD
- Mid-year 2026: Initiation of Ascend, the second Phase 3 study of DT120 ODT in MDD
Expanding Pipeline Beyond Core Indications
Beyond its flagship GAD and MDD programs, Definium continues advancing its early-stage pipeline. The company has dosed the first patient in a Phase 2a study of DT402 (search) in adults with autism spectrum disorder (search) (ASD), with initial data expected in 2026.
"We are unwavering in our mission to forge a new era of psychiatry by applying scientific rigor to psychedelics," Barrow stated. "By retracing LSD to its origins, we aim to fully realize its clinical potential as a safe and transformative therapeutic."
Strategic Leadership Addition
To support its transition toward commercialization, Definium appointed Roger Adsett to its Board of Directors. Adsett brings over two decades of biopharmaceutical experience, currently serving as Chief Operating Officer of Insmed, where he has overseen commercial strategy and the successful launches of ARIKAYCE® and BRINSUPRI®.
"Roger is a respected and proven leader with deep experience building high-performing commercial organizations and guiding transformational therapies from launch to meaningful market impact," said Barrow. Adsett previously held senior leadership positions at Shire and AstraZeneca, including roles in the launches of blockbuster therapies Nexium® and Symbicort®.
Mission-Driven Approach to Mental Health
The rebrand to Definium Therapeutics (search) emphasizes the company's commitment to developing treatments that address underlying causes of psychiatric and neurological disorders rather than providing transient symptom reduction. According to Chief Corporate Affairs Officer Stephanie Fagan, "'Definio' speaks to our clear sense of direction and scientific precision, and 'infinitum' to being open to what hasn't been done before and the impact we can have on the world."
The company plans to host an Analyst Day in the second quarter of 2026, highlighting its pivotal programs, pipeline, and path to commercialization as it prepares for potential product launches in the world's largest psychiatric markets.